Jm Ng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jm Ng has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Bj Allan
Diabetes Centre, Michael White Centre, Hull Royal Infirmary, Hull, UK
2 shared publications- Duane Daniel Mellor
Department of Nutrition and Dietetics University Hospitals of Leicester NHS Trust Leicester UK
2 shared publications Sl Atkin
Professor in Diabetes and Endocrinology University of Hull, Hull, UK
2 shared publicationsBelinda J. Allan
Diabetes Centre, Michael White Centre, Hull Royal Infirmary, 220-226 Anlaby Road, Hull HU3 2RW, United Kingdom
1 shared publicationC Walton
Diabetes Centre, Hull Royal Infirmary, 220-236 Anlaby Road, Hull HU3 2RW, UK
1 shared publicationD Narayanan
Department of Clinical Biochemistry, Hull Royal Infirmary, Hull, UK
1 shared publication
Latest Publications
- Open Access
- 26 August 2010
- Published by American Diabetes Association in Diabetes Care
- Vol. 33 (11) , 2310-2313
The Effect of Iron and Erythropoietin Treatment on the A1C of Patients With Diabetes and Chronic Kidney Disease
OBJECTIVE: To examine the effect of intravenous iron and erythropoietin-stimulating agents (ESAs) on glycemic control and A1C of patients with diabetes and chronic kidney disease (CKD). RESEARCH DESIGN AND METHODS: This was a prospective study of patients with type 2 diabetes and CKD stage IIIB or IV undergoing intravenous iron (group A) and/or ESA (group B). Full blood profiles were determined over the study period. Glycemic control was monitored using A1C, seven-point daily glucose three times weekly, and continuous glucose monitoring (CGM). RESULTS: There were 15 patients in both group A and group B. Mean A1C (95% CI) values fell in both groups (7.40% [6.60–8.19] to 6.96% [6.27–7.25], P < 0.01, with intravenous iron and 7.31% [6.42–8.54] to 6.63% [6.03–7.36], P = 0.013, ESA). There was no change in mean blood glucose in group A (9.55 mmol/l [8.20–10.90] vs. 9.71 mmol/l [8.29–11.13], P = 0.07) and in group B (8.72 mmol/l [7.31–10.12] vs. 8.78 mmol/l [7.47–9.99], P = 0.61) over the study period. Hemoglobin and hematocrit values significantly increased following both treatments. There was no linear relationship found between the change in A1C values and the rise of hemoglobin following either treatment. CONCLUSIONS: Both iron and ESA cause a significant fall in A1C values without a change to glycemic control in patients with diabetes and CKD. At the present time, regular capillary glucose measurements and the concurrent use of CGM remain the best alternative measurements of glycemic control in this patient group.
- 26 August 2010
- Published by American Diabetes Association in Diabetes Care
- Vol. 33 (11) , 2310-2313
Open AccessThe Effect of Iron and Erythropoietin Treatment on the A1C of Patients With Diabetes and Chronic Kidney Disease
OBJECTIVE: To examine the effect of intravenous iron and erythropoietin-stimulating agents (ESAs) on glycemic control and A1C of patients with diabetes and chronic kidney disease (CKD). RESEARCH DESIGN AND METHODS: This was a prospective study of patients with type 2 diabetes and CKD stage IIIB or IV undergoing intravenous iron (group A) and/or ESA (group B). Full blood profiles were determined over the study period. Glycemic control was monitored using A1C, seven-point daily glucose three times weekly, and continuous glucose monitoring (CGM). RESULTS: There were 15 patients in both group A and group B. Mean A1C (95% CI) values fell in both groups (7.40% [6.60–8.19] to 6.96% [6.27–7.25], P < 0.01, with intravenous iron and 7.31% [6.42–8.54] to 6.63% [6.03–7.36], P = 0.013, ESA). There was no change in mean blood glucose in group A (9.55 mmol/l [8.20–10.90] vs. 9.71 mmol/l [8.29–11.13], P = 0.07) and in group B (8.72 mmol/l [7.31–10.12] vs. 8.78 mmol/l [7.47–9.99], P = 0.61) over the study period. Hemoglobin and hematocrit values significantly increased following both treatments. There was no linear relationship found between the change in A1C values and the rise of hemoglobin following either treatment. CONCLUSIONS: Both iron and ESA cause a significant fall in A1C values without a change to glycemic control in patients with diabetes and CKD. At the present time, regular capillary glucose measurements and the concurrent use of CGM remain the best alternative measurements of glycemic control in this patient group.
- Open Access
- 22 July 2010
- Published by Wiley in Practical Diabetes International
- Vol. 27 (6) , 225-226
Ward staffing levels significantly affect timing of insulin administration in hospital
- 22 July 2010
- Published by Wiley in Practical Diabetes International
- Vol. 27 (6) , 225-226
Open AccessWard staffing levels significantly affect timing of insulin administration in hospital
- 1 April 2010
- Published by Elsevier in Primary Care Diabetes
- Vol. 4 (1) , 61-63
Sulphonyurea as a cause of severe hypoglycaemia in the community
- 1 April 2010
- Published by Elsevier in Primary Care Diabetes
- Vol. 4 (1) , 61-63
Sulphonyurea as a cause of severe hypoglycaemia in the community
- Open Access
- 1 April 2009
- Published by Wiley in Practical Diabetes International
- Vol. 26 (3) , 98
Post‐natal follow up of patients with gestational diabetes: one year onward
- 1 April 2009
- Published by Wiley in Practical Diabetes International
- Vol. 26 (3) , 98
Open AccessPost‐natal follow up of patients with gestational diabetes: one year onward
- Open Access
- 1 March 2009
- Published by Wiley in Practical Diabetes International
- Vol. 26 (2) , 54
Exenatide initiation in type 2 diabetes: do more people discontinue treatment after individual rather than group starts?
- 1 March 2009
- Published by Wiley in Practical Diabetes International
- Vol. 26 (2) , 54
Open AccessExenatide initiation in type 2 diabetes: do more people discontinue treatment after individual rather than group starts?